Neutralization of inhibitory pathways in lymphocytes
US10870700B2 · kind B2 · utility
6Cited by
10References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 20, 2017 |
| Grant date | Dec 22, 2020 |
| Priority date | — |
| Expiry date | Sep 26, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.